Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Drug Discov Devel. 2004 Jul;7(4):487-97.

Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases.

Author information

1
Bristol-Myers Squibb Pharmaceutical Research Institute, Department of Neuroscience Chemistry, 5 Research Parkway, Wallingford, CT 06492, USA. paul.j.gilligan@bms.com

Abstract

Corticotropin-releasing factor (CRF) co-ordinates the neural, endocrine and immune responses of the body to stress. Several studies have implicated CRF in the etiology of anxiety, depression, substance abuse, stress-related gastrointestinal disorders and preterm labor, and intensive research into the design of safe and effective CRF antagonists is currently being pursued in several laboratories. Recently, improvements have been made not only in brain penetrance and in vivo activity in preclinical models for anxiety, depression and irritable bowel syndrome, but also in structural diversity for these compounds. Clinical data for R-121919 (NBI-30775; Neurocrine Biosciences Inc) raises the expectation that safe and potent CRF antagonists might be useful as drugs for the treatment of human diseases.

PMID:
15338958
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center